Bard
This article was originally published in The Gray Sheet
Executive Summary
Programmable pain pump development effort is abandoned, resulting in a Q4 write-off of $3-$6 mil. Bard has no plans to pursue any other pain management product line "at this point," Chairman and CEO Timothy Ring reported during a Jan. 28 earnings call. Revenue for 2003 totaled $1.43 bil., up 13%; net income of $168.5 mil., up 8.7%, includes a $35.5 mil. after-tax charge resulting from a brachytherapy lawsuit (1"The Gray Sheet" Jan. 5, 2004, In Brief)...
You may also be interested in...
Nelson N. Stone, MD, v. Bard
Company will file post-trial motions to set aside Manhattan district court's Dec. 19 ruling that it should pay $23 mil. for breach of contract and $35 mil. for fraud to urologists who created ProSeed, a brachytherapy seed practice management and training group. The plaintiffs claim that following its purchase of ProSeed in 1998, Bard failed "to use appropriate efforts to promote" growth of the business, "failed to pay consideration due under the agreement and induced the sale of the company by misrepresentation," Bard discloses in an 8-K SEC filing. If the verdict is not set aside or the award amount reduced, Bard plans to appeal. The firm expects the post-trial motions to be decided in Q1...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.